Previous Article | Next Article 
Journal of Clinical Microbiology, November 2001, p. 4184-4186, Vol. 39, No. 11
MRC Centre for Molecular and Cellular
Biology, Department of Medical Biochemistry,1
and Department of Pediatrics and Child
Health,2 University of Stellenbosch,
Stellenbosch, South Africa
Received 26 March 2001/Returned for modification 19 July
2001/Accepted 9 August 2001
A mutation (C-to-T transition) at position 491 of the
rrs gene was identified in a Mycobacterium
tuberculosis strain family (n = 208 isolates)
that was predominant in a suburb of Cape Town, South Africa. This
nucleotide change is not involved in streptomycin resistance, and we
suggest caution in assuming that all mutations in genes targeted by
antituberculosis drugs confer drug resistance.
Multiple-drug-resistant
Mycobacterium tuberculosis is a major concern to health
authorities worldwide (1, 7, 8, 12). Unlike the antibiotic
resistance in many bacterial species, which is acquired by gene
transduction, conjugation, or transformation, the drug resistance in
M. tuberculosis is genomically based. Resistance to
first-line antituberculosis drugs has been linked to mutations in nine
genes, viz., katG, inhA, aphC, and kasA for
isoniazid resistance, rpoB for rifampin resistance,
rpsL and rrs for streptomycin (SM) resistance,
embB for ethambutol resistance, and pncA for pyrazinamide resistance (6). Mutations identified in these genes have been associated with drug resistance based on their absence
in drug-susceptible isolates (6). Multiple-drug resistance results from the accumulation of mutations in different genes (2,
5). Analysis of these mutations has been proposed as a powerful
tool for rapid prediction of drug resistance (6), thereby
enhancing the efficiency of diagnosis and limiting the spread of
drug-resistant strains.
In this study we used mutational analysis (14) and DNA
fingerprinting (11) to analyze M. tuberculosis
isolates collected from two high-incidence communities in Cape Town,
South Africa. Mutation analysis was done using a PCR-based dot blot
hybridization technique to identify mutations associated with
resistance to isoniazid, rifampin, SM, and ethambutol (6).
To ensure accurate genotypeclassification of drug resistance, amplified
products of the reference strain H37Rv and those from fully susceptible isolates and resistant isolates (characterized by culture testing and
gene sequencing) were included on each blot as wild-type and mutant
controls (13, 15). Using the dot blot hybridization method in combination with an oligonucleotide complementary to the
mutant sequence, we detected a mutation in the rrs gene of an SM-susceptible clinical isolate (isolate 208). Subsequent automated sequence analysis with an ABI PRISM (model 3100; Applied Biosystems) analyzer confirmed a C-to-T transition at position 491 of the rrs gene, a mutation which has previously been associated
with resistance to SM (4, 12).
Characterization of isolate 208 by IS6110 DNA fingerprinting
showed the presence of 14 hybridizing bands. Analysis of the local
M. tuberculosis restriction fragment length polymorphism (RFLP) database (16) of the two communities in the study
classified the isolate as belonging to a predominant strain family
designated family 11, a family representing 21.4% of all infecting
strains (n = 208 individual patients)
(17). The RFLP pattern of representative isolates of
family 11 is given in Fig. 1. Dot blot
hybridization analysis of 71 selected representative isolates of this
strain family showed that they all had the C-to-T transition at
position 491 in the rrs gene. In contrast, dot blot
hybridization analysis of isolates (n = 184)
representative of other strain families (16, 17) failed to
identify this mutation. This suggests that the C-to-T transition at
position 491 in the rrs gene is specific to family 11. Previously this strain family was classified as belonging to pathogenic
group 2, according to the sequences of the katG and
gyrA genes (17). Interestingly, family
11 isolates are shown to form part of an independently evolving group,
which has branched recently from a large clade of strain families all classified as pathogenic group 2. This would suggest that the nucleotide change at position 491 of the rrs gene is more
recent than the polymorphism at position 463 of the katG
gene used for the group classification (9). The nucleotide
change at position 491 of the rrs gene may therefore be
useful to further subclassify pathogenic group 2 isolates.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.4184-4186.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Sequence Polymorphism in the rrs Gene of
Mycobacterium tuberculosis Is Deeply Rooted within an
Evolutionary Clade and Is Not Associated with Streptomycin
Resistance
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
View larger version (90K):
[in a new window]
FIG. 1.
RFLP pattern of representative isolates of family 11.
To study the relationship between the C-to-T transition at position 491 of the rrs gene and drug susceptibility, tests at critical concentrations of 0.1, 1.5, and 2 µg of SM per ml were performed by the 1% proportion method (3) on 10 randomly selected isolates of family 11. All of the isolates tested were susceptible at these concentrations. Review of records from previous drug susceptibility testing of the 208 patients infected with a family 11 strain indicated that the infecting strain was resistant to SM in three patients. Retesting of the phenotypic susceptibilities of these three isolates demonstrated that they were susceptible to concentrations of 0.1, 1.5, and 2 µg of SM per ml. Thus, all of the isolates tested were fully susceptible to SM at a concentration 20 times lower than the standard critical concentration for discriminating between drug-resistant and -susceptible isolates.
Previous reports described nucleotide changes at position 491 of the rrs gene in two clinical isolates resistant to SM (4, 10). However, no information was given about the MICs for these two isolates. Based on the results presented in this study and in contrast to the previous reports, we conclude that the nucleotide change at position 491 is a polymorphism that is not associated with drug resistance in this strain family. Although numerous studies have shown associations between different mutations and drug resistance, there is limited data to indicate that such mutations are the causative mechanisms for resistance. This study not only further questions the assumption that all mutations confer resistance in genes in which mutations have been associated with antituberculosis drug resistance but also highlights the importance of establishing the causal relationship between any given mutation and drug resistance. This is particularly relevant in view of numerous reports proposing the use of molecular techniques to identify drug resistance.
| |
ACKNOWLEDGMENTS |
|---|
We thank Tygerberg Hospital, the Harry Crossley Foundation, and the IAEA (projects SAF6/003 and CRP 9925) for financial assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medical Biochemistry, University of Stellenbosch, Stellenbosch, South Africa. Phone: 27-21-9389251. Fax: 27-21-9317810. E-mail: TV{at}gerga.sun.ac.za.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Edlin, B. R., J. I. Tokars, M. H. Grieco, J. T. Crawford, J. Williams, E. M. Sordillo, K. R. Ong, J. O. Kilburn, S. W. Dooley, K. G. Castro, W. R. Jarvis, and S. D. Holmberg. 1992. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:1514-1521[Abstract]. |
| 2. | Heym, B., N. Honore, P. C. Truffat, A. Banerjee, C. Schurra, W. R. Jacobs, J. D. van Embden, J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-298[CrossRef][Medline]. |
| 3. | Kleeberg, H. H., Z. Blacklock, F. Boulahbal, H. L. David, H. Fink, E. M. S. Gatner, J. Grosset, J. Juhlin, R. Kallich, I. Kawamura, J. O. Kilburn, C. G. Kleeberg, F. Mandler, S. R. Pattyn, K. F. Petersen, H. Reutgen, E. H. Runon, H. Saito, K. H. Schröder, M. F. Stander, I. Szabo, S. Takahashi, S. P. Tripathy, L. Tinka, and B. Vergmann. 1985. A simple method of testing drug susceptibility of Mycobacterium tuberculosis: a report of an international collaborative study. Bull. Int. Union Tuberc. 60:147-150. |
| 4. |
Meier, A.,
P. Kirschner,
F. C. Bange,
U. Vogel, and E. C. Böttger.
1994.
Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance.
Antimicrob. Agents Chemother.
38:228-233 |
| 5. | Morris, S., G. Han Bai, P. Suffys, L. Portillo-Gomez, M. Fairchok, and D. Rouse. 1995. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infect. Dis. 171:954-960[Medline]. |
| 6. | Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 79:3-29[CrossRef][Medline]. |
| 7. | Rittaco, V., M. Di Lonardo, A. Reniero, M. Ambroggi, L. Barrera, A. Dambrosi, B. Lopez, N. Isola, and I. N. de Kantor. 1997. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J. Infect. Dis. 176:637-642[Medline]. |
| 8. | Rullan, J. V., D. Herrera, R. Cano, V. Moreno, P. Godoy, E. F. Peiro, J. Castell, C. Ibanez, A. Ortega, L. S. Agudo, and F. Pozo. 1996. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg. Infect. Dis. 2:125-129[Medline]. |
| 9. |
Sreevatsan, S.,
X. Pan,
K. E. Stockbauer,
N. D. Cornell,
B. N. Kreiswirth,
T. C. Whittam, and J. M. Musser.
1997.
Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination.
Proc. Natl. Acad. Sci. USA
94:9869-9874 |
| 10. | Sreevatsan, S., X. Pan, K. E. Stockbauer, D. L. Williams, B. N. Kreiswirth, and J. M. Musser. 1996. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob. Agents Chemother. 40:1024-1026[Abstract]. |
| 11. |
van Embden, J. D. A.,
M. D. Cave,
J. T. Crawford,
J. W. Dale,
K. D. Eisenach,
B. Gicquel,
P. Hermans,
C. Martin,
R. McAdam,
T. M. Shinnick, and P. M. Small.
1993.
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.
J. Clin. Microbiol.
31:406-409 |
| 12. | Van Rie, A., R. M. Warren, N. Beyers, R. P. Gie, C. N. Classen, M. Richardson, S. L. Sampson, T. C. Victor, and P. D. van Helden. 1999. Transmission of a multidrug-resistant Mycobacterium tuberculosis strain among non-institutionalized, human immunodeficiency virus-seronegative patients. J. Infect. Dis. 180:1174-1179. |
| 13. |
Van Rie, A.,
R. Warren,
I. Mshanga,
A. M. Jordaan,
G. D. van der Spuy,
M. Richardson,
J. Simpson,
R. P. Gie,
D. A. Enarson,
N. Beyers,
P. D. van Helden, and T. C. Victor.
2001.
Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community.
J. Clin. Microbiol.
39:636-641 |
| 14. | Victor, T. C., A. M. Jordaan, A. Van Rie, G. D. van Der Spuy, M. Richardson, P. D. van Helden, and R. Warren. 1999. Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. Tuber. Lung Dis. 79:343-348[CrossRef][Medline]. |
| 15. |
Victor, T. C.,
R. Warren,
J. L. Butt,
A. M. Jordaan,
J. V. Felix,
A. Venter,
F. A. Sirgel,
H. S. Schaaf,
P. R. Donald,
M. Richardson,
M. H. Cynamon, and P. D. van Helden.
1997.
Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis.
J. Med. Microbiol.
46:847-857 |
| 16. | Warren, R., M. Richardson, G. van der Spuy, T. Victor, S. Sampson, N. Beyers, and P. van Helden. 1999. DNA fingerprinting and molecular epidemiology of tuberculosis: use and interpretation in an epidemic setting. Electrophoresis 20:1807-1812[CrossRef][Medline]. |
| 17. | Warren, R. M., S. L. Sampson, M. Richardson, G. D. Van der Spuy, C. J. Lombard, T. C. Victor, and P. D. Van Helden. 2000. Mapping of IS6110 flanking regions in clinical isolates of Mycobacterium tuberculosis demonstrates genome plasticity. Mol. Microbiol. 37:1405-1416[CrossRef][Medline]. |
Journal of Clinical Microbiology, November 2001, p. 4184-4186, Vol. 39, No. 11
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.11.4184-4186.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ho, Y. M., Sun, Y.-J., Wong, S.-Y., Lee, A. S. G.
(2009). Contribution of dfrA and inhA Mutations to the Detection of Isoniazid-Resistant Mycobacterium tuberculosis Isolates. Antimicrob. Agents Chemother.
53: 4010-4012
[Abstract] [Full Text] -
Warren, R. M., Victor, T. C., Streicher, E. M., Richardson, M., van der Spuy, G. D., Johnson, R., Chihota, V. N., Locht, C., Supply, P., van Helden, P. D.
(2004). Clonal Expansion of a Globally Disseminated Lineage of Mycobacterium tuberculosis with Low IS6110 Copy Numbers. J. Clin. Microbiol.
42: 5774-5782
[Abstract] [Full Text] -
Victor, T. C., de Haas, P. E. W., Jordaan, A. M., van der Spuy, G. D., Richardson, M., van Soolingen, D., van Helden, P. D., Warren, R.
(2004). Molecular Characteristics and Global Spread of Mycobacterium tuberculosis with a Western Cape F11 Genotype. J. Clin. Microbiol.
42: 769-772
[Abstract] [Full Text] -
Ramaswamy, S. V., Dou, S.-J., Rendon, A., Yang, Z., Cave, M. D., Graviss, E. A.
(2004). Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Monterrey, Mexico. J Med Microbiol
53: 107-113
[Abstract] [Full Text] -
Kruuner, A., Jureen, P., Levina, K., Ghebremichael, S., Hoffner, S.
(2003). Discordant Resistance to Kanamycin and Amikacin in Drug-Resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother.
47: 2971-2973
[Abstract] [Full Text] -
Warren, R. M., Streicher, E. M., Sampson, S. L., van der Spuy, G. D., Richardson, M., Nguyen, D., Behr, M. A., Victor, T. C., van Helden, P. D.
(2002). Microevolution of the Direct Repeat Region of Mycobacterium tuberculosis: Implications for Interpretation of Spoligotyping Data. J. Clin. Microbiol.
40: 4457-4465
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»